| Overview |
| bs-4072R-PerCP |
| CBL2 (Tyr700) Polyclonal Antibody, PerCP Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Dog, Cow, Pig, Horse |
| Specifications |
| PerCP |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human C CBL around the phosphorylation site of Tyr700 |
| Tyr700 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 867 |
| Cytoplasm, Cell membrane |
| C CBL Tyr700; CBL2 Tyr700; CBL2 Y700; p-CBL2 Tyr700; p-CBL2 Y700; C CBL; Cas-Br-M murine ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik; CBL_HUMAN. |
| This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012] |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz